PLoS ONE 2015-01-01

A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum.

David Rojo, Gisele A B Canuto, Emerson A Castilho-Martins, Marina F M Tavares, Coral Barbas, Ángeles López-Gonzálvez, Luis Rivas

Index: PLoS ONE 10 , e0130675, (2015)

Full Text: HTML

Abstract

There is a rising resistance against antimony drugs, the gold-standard for treatment until some years ago. That is a serious problem due to the paucity of drugs in current clinical use. In a research to reveal how these drugs affect the parasite during treatment and to unravel the underlying basis for their resistance, we have employed metabolomics to study treatment in Leishmania infantum promastigotes. This was accomplished first through the untargeted analysis of metabolic snapshots of treated and untreated parasites both resistant and responders, utilizing a multiplatform approach to give the widest as possible coverage of the metabolome, and additionally through novel monitoring of the origin of the detected alterations through a 13C traceability experiment. Our data stress a multi-target metabolic alteration with treatment, affecting in particular the cell redox system that is essential to cope with detoxification and biosynthetic processes. Additionally, relevant changes were noted in amino acid metabolism. Our results are in agreement with other authors studying other Leishmania species.

Related Compounds

Structure Name/CAS No. Articles
Chloroform Structure Chloroform
CAS:67-66-3
Acetonitrile Structure Acetonitrile
CAS:75-05-8
Hydrochloric acid Structure Hydrochloric acid
CAS:7647-01-0
Methanol Structure Methanol
CAS:67-56-1
Isopropanol Structure Isopropanol
CAS:67-63-0
Formic Acid Structure Formic Acid
CAS:64-18-6
Pyridine Structure Pyridine
CAS:110-86-1
Water Structure Water
CAS:7732-18-5
Chlorotrimethylsilane Structure Chlorotrimethylsilane
CAS:75-77-4
Suplatast Tosilate Structure Suplatast Tosilate
CAS:94055-76-2